Compare Stocks: ROIV, ASND, APLS, and ELAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$41.03	$34.89	$16.10 ▼ $41.14	$5.25B	-0.24	7.54 million shs	68.61 million shs
ASND Ascendis Pharma A/S	$230.05 +2.0%	$251.52	$186.05 ▼ $282.15	$14.35B	0.35	698,358 shs	747,514 shs
ELAN Elanco Animal Health	$22.45 +0.6%	$24.04	$19.40 ▼ $27.98	$11.22B	1.68	5.67 million shs	6.34 million shs
ROIV Roivant Sciences	$36.98 +3.3%	$36.50	$14.86 ▼ $42.50	$26.71B	1.12	6.46 million shs	6.97 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+83.42%
ASND Ascendis Pharma A/S	0.00%	-4.70%	-9.00%	-14.45%	+17.51%
ELAN Elanco Animal Health	0.00%	+0.08%	-7.25%	-9.50%	+14.18%
ROIV Roivant Sciences	0.00%	-9.98%	+3.14%	+3.08%	+135.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$41.03	$34.89	$16.10 ▼ $41.14	$5.25B	-0.24	7.54 million shs	68.61 million shs
ASND Ascendis Pharma A/S	$230.05 +2.0%	$251.52	$186.05 ▼ $282.15	$14.35B	0.35	698,358 shs	747,514 shs
ELAN Elanco Animal Health	$22.45 +0.6%	$24.04	$19.40 ▼ $27.98	$11.22B	1.68	5.67 million shs	6.34 million shs
ROIV Roivant Sciences	$36.98 +3.3%	$36.50	$14.86 ▼ $42.50	$26.71B	1.12	6.46 million shs	6.97 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+83.42%
ASND Ascendis Pharma A/S	0.00%	-4.70%	-9.00%	-14.45%	+17.51%
ELAN Elanco Animal Health	0.00%	+0.08%	-7.25%	-9.50%	+14.18%
ROIV Roivant Sciences	0.00%	-9.98%	+3.14%	+3.08%	+135.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.14	Hold	$38.88	-5.25% Downside
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	35.08% Upside
ELAN Elanco Animal Health	2.75	Moderate Buy	$29.70	32.31% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	23.41% Upside

Current Analyst Ratings Breakdown

Latest ROIV, ASND, APLS, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00
9/15/2026	ASND Ascendis Pharma A/S	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$287.00
9/10/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$344.00
9/10/2026	ASND Ascendis Pharma A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
9/9/2026	ROIV Roivant Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
9/9/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$1.11B	4.75	$0.21 per share	196.33	$3.24 per share	12.66
ASND Ascendis Pharma A/S	$814.57M	17.62	N/A	N/A	($2.97) per share	-77.46
ELAN Elanco Animal Health	$4.72B	2.38	$2.34 per share	9.61	$13.18 per share	1.70
ROIV Roivant Sciences	$8.26M	3,233.82	N/A	N/A	$7.35 per share	5.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	$22.39M	$1.02	40.23	N/A	N/A	12.06%	39.71%	13.20%	N/A
ASND Ascendis Pharma A/S	-$258M	$12.89	17.85	25.94	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.40	1.59	-3.96%	8.13%	3.99%	11/6/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest ROIV, ASND, APLS, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	0.87	3.63	3.16
ASND Ascendis Pharma A/S	0.27	2.99	2.32
ELAN Elanco Animal Health	0.58	2.05	1.10
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
ASND Ascendis Pharma A/S	N/A
ELAN Elanco Animal Health	97.48%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
ASND Ascendis Pharma A/S	40.00%
ELAN Elanco Animal Health	1.14%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	128.02 million	119.70 million	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

ROIV, ASND, APLS, and ELAN Headlines

Recent News About These Companies

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

September 28 at 4:01 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27 at 2:54 PM | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

September 27 at 2:54 PM | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

September 24, 2026 | theglobeandmail.com

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

September 24, 2026 | finance.yahoo.com

Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus

September 23, 2026 | finance.yahoo.com

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026 | globenewswire.com

Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM

September 22, 2026 | marketscreener.comM

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

September 22, 2026 | insidermonkey.com

Head-To-Head Contrast: Roivant Sciences (NASDAQ:ROIV) & Emergent Biosolutions (NYSE:EBS)

September 22, 2026 | americanbankingnews.com

Vivek Ramaswamy Sold an Estimated $1.2B in Stock, Now Could Become the Third-Richest US Elected Official

September 21, 2026 | ibtimes.co.ukI

Vivek Ramaswamy’s $2.3 Billion fortune puts him on track to be one of America’s richest governors

September 21, 2026 | financialexpress.comF

What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?

September 18, 2026 | finance.yahoo.com

Roivant Shareholders Approve Directors and Governance Matters

September 18, 2026 | tipranks.com

Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares

September 18, 2026 | insidertrades.com

Stifel initiates coverage of Roivant Sciences with buy rating

September 17, 2026 | msn.com

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares of Stock

September 17, 2026 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts

September 17, 2026 | americanbankingnews.com

California State Teachers Retirement System Raises Holdings in Roivant Sciences Ltd. $ROIV

September 14, 2026 | marketbeat.com

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

September 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ROIV, ASND, APLS, and ELAN Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ascendis Pharma A/S NASDAQ:ASND

$230.05 +4.45 (+1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$230.01 -0.04 (-0.02%)

As of 07:51 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Elanco Animal Health NYSE:ELAN

$22.45 +0.14 (+0.62%)

Closing price 03:59 PM Eastern

Extended Trading

$22.36 -0.09 (-0.39%)

As of 07:33 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Roivant Sciences NASDAQ:ROIV

$36.98 +1.18 (+3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$38.28 +1.30 (+3.53%)

As of 07:48 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, ASND, APLS, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, ASND, APLS, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, ASND, APLS, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, ASND, APLS, and ELAN Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Ascendis Pharma A/S NASDAQ:ASND

Elanco Animal Health NYSE:ELAN

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, ASND, APLS, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, ASND, APLS, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, ASND, APLS, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, ASND, APLS, and ELAN Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Ascendis Pharma A/S NASDAQ:ASND

Elanco Animal Health NYSE:ELAN

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools